secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001708599-25-000042
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252
--------------------------------------------------------------------------------

- Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.
- Preferred stock carries 8% cumulative annual dividend, paid in kind; convertible at $5.18 per common share.
- Proceeds to support SER-252 (POZ-apomorphine) Phase 1 trial initiation in Q4 2025 for advanced Parkinson's.
- Financing from strategic shareholders; conversion triggers include stock price doubling or $20M+ equity raise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/0001708599-25-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/ser-20250408.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer